Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, 830-0011, Japan.
Gastric Cancer. 2014 Jan;17(1):97-106. doi: 10.1007/s10120-013-0255-9. Epub 2013 Apr 5.
CD133 is one of the most important stem cell markers in solid cancers. Some recent reports have described a possible relationship between CD133 and hypoxia-inducing factor-1-alpha (HIF-1α). The aim of this study was to clarify the clinical role of CD133 expression in gastric cancer and to investigate the correlation between CD133 expression and HIF-1α expression.
We studied 189 gastric cancer patients who underwent gastrectomy at Kurume University Hospital. CD133 and HIF-1α expression was examined using immunohistochemical staining. Fifty-six cases were CD133 positive, and they were divided into two expression types: luminal expression of the gland and cytoplasmic expression. We investigated the relationship among CD133 expression types, clinicopathological variables, prognosis, and HIF-1α expression.
When comparing clinicopathological variables, expression of CD133 in the cytoplasm was related to metastasis and tumor progression. However, this relationship was not observed with luminal expression of the gland type. The survival rate in patients with cytoplasmic CD133 expression was significantly worse than that in the CD133-negative group. This relationship was observed in the survival rate of the adjuvant chemotherapy group and the curative resection group. Multivariate analysis revealed that the expression of CD133 in the cytoplasm was an independent prognostic factor in gastric cancer. Regarding the correlation between CD133 expression and HIF-1α expression, the HIF-1α positive rate was lower in patients with CD133 luminal expression of the gland type and higher in patients with cytoplasmic expression of CD133.
Gastric cancer cells with CD133 expression in the cytoplasm were cells with high potential for malignancy, and this phenotype was associated with cancer progression, chemotherapy resistance, recurrence, and poor prognosis. Cytoplasmic expression of CD133 may be a useful prognostic marker in gastric cancer. Significant correlation was observed between HIF-1α expression and the immunohistochemical staining pattern of CD133.
CD133 是实体瘤中最重要的干细胞标志物之一。一些最新的报告描述了 CD133 与缺氧诱导因子-1 阿尔法（HIF-1α）之间可能存在的关系。本研究旨在阐明 CD133 在胃癌中的临床作用，并探讨 CD133 表达与 HIF-1α 表达之间的相关性。
我们研究了在久留米大学医院接受胃切除术的 189 名胃癌患者。使用免疫组织化学染色法检测 CD133 和 HIF-1α 的表达。56 例 CD133 阳性病例，分为两种表达类型：腺腔的管腔表达和细胞质表达。我们研究了 CD133 表达类型、临床病理变量、预后和 HIF-1α 表达之间的关系。
当比较临床病理变量时，细胞质中 CD133 的表达与转移和肿瘤进展有关。然而，这种关系在腺腔的管腔表达类型中没有观察到。细胞质中 CD133 表达的患者的生存率明显低于 CD133 阴性组。这种关系在辅助化疗组和根治性切除组的生存率中都观察到。多变量分析显示，细胞质中 CD133 的表达是胃癌的独立预后因素。关于 CD133 表达与 HIF-1α 表达之间的相关性，CD133 腺腔管腔表达的患者中 HIF-1α 的阳性率较低，而细胞质中 CD133 表达的患者中 HIF-1α 的阳性率较高。
具有 CD133 细胞质表达的胃癌细胞是具有高恶性潜能的细胞，这种表型与癌症进展、化疗耐药、复发和不良预后有关。细胞质中 CD133 的表达可能是胃癌的一个有用的预后标志物。HIF-1α 的表达与 CD133 的免疫组织化学染色模式之间存在显著相关性。
